<DOC>
	<DOCNO>NCT02126904</DOCNO>
	<brief_summary>The investigator compare time recurrence ranibizumab aflibercept load patient AMD .</brief_summary>
	<brief_title>Comparison Time Recurrence Between Ranibizumab Aflibercept</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>They must BCVA good 20/400 three consecutive induction treatment ranibizumab aflibercept . patient eye disease could potentially influence visual acuity study eye , glaucoma , macular hole , diabetic retinopathy , rhegmatogenous retinal detachment .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>